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ABSTRACT 
The objective of the present work to develop extended-release floating matrix tablets of Atazanavir  (ATZ), which were designed to prolong the 
gastric residence time and drug release after oral administration. Different grades of ethyl cellulose (i.e. EC N20, EC N22, EC N45, EC N50, EC 
N100 etc.,) as floating aids and Hydroxypropyl methylcellulose (i.e. HPMC K100M) were used to get the desired floating and prolonged release 
profile over an extended period. All the formulations extended the drug release up to 24 hours and more and the formulations were optimized 
based on the all physicochemical properties. The drug release and floating property depended on the floating aid, polymer type,  and their 
proportions.. The formulation prepared with EC and HPMC K100M has more floating time than the formulation prepared with the EC alone. The 
optimized formulation (F10) prepared with a combination of EC N100 and HPMC K100M was evaluated for In vivo radiographic study, which 
shows the floating property for up to 9 hours. The DSC study shows that there is no drug-polymer interaction. This study gives the preliminary 
idea about the development of the floating drug delivery systems of Atazanavir without the use of a gas generating agent.  
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INTRODUCTION 
The oral route is considered as the most promising route of 
drug delivery1. But most of the oral dosage forms possess 
several physiological limitations such as variable 
gastrointestinal transit, because of variable gastric emptying 
leading to non-uniform absorption profiles, incomplete drug 
release and shorter residence time of the dosage form in the 
stomach 2. This leads to incomplete absorption of drugs 
having an absorption window especially in the upper part of 
the small intestine, as once the drug passes down the 
absorption site, the remaining quantity goes unabsorbed3. 
The gastric emptying of dosage forms in humans is affected 
by several factors because of which wide inter- and intra-
subject variations are observed 4. In recent years scientific 
and technological advancements have been made in the 
research and development of controlled release oral drug 
delivery systems by overcoming physiological adversities 
like short gastric residence time and unpredictable gastric 
emptying time5. To date, their usefulness is limited to 
systemic administration. So, to minimize drug degradation 
and loss, to prevent harmful side-effects and to increase 
drug bioavailability and the fraction of the drug accumulated 
in the required zone, various drug delivery and drug 
targeting systems are currently under development6. The 
key point with traditional drug administration is that the 
blood level of the agent should remain between a maximum 
value, which may represent a toxic level, and minimum 
values, below which the drug is no longer effective 7-11. 
The main aim and object of this present work is to formulate 
non-effervescent extended-release floating matrix tablets 
using different polymeric concentrations and evaluating all 
formulations and notifying the optimized formulation. 
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MATERIAL AND METHODS 
MATERIALS 
ATZ sulfate was received as a gift sample from Aurobindo 
Pharma Ltd, Hyderabad, India. Hydroxypropyl 
methylcellulose (HPMC K100M) procured from DOW 
chemical company, USA. Ethylcellulose (EC) purchased from 
Aurobindo Pharma Ltd, Hyderabad, India. Magnesium 
Stearate procured from Himedia Pvt. Ltd., Mumbai and 
Hydrochloric Acid (HCl) procured from Merck specialties 
Pvt. Ltd., Mumbai, India. 
METHODS 
Pre-formulation studies 
Pre-formulation is the first step in the rational development 
of dosage forms. The physical properties of powder mixture 
were evaluated for the angle of repose (ɵ), Carr’s index or 
compressibility index (%) and Hausner’s ratio 12-14. 
 
Table 1: Physicochemical properties of powder blends (F1 to F16) 
Formulation 
code 
Angle of repose (ɵ) Carr’s index (%) Hausner’s ratio 
F1 27.63±0.35 10.45±0.15 1.08±0.16 
F2 26.89±0.28 11.36±0.23 1.20±0.12 
F3 23.04±0.61 10.82±0.35 1.06±0.03 
F4 25.36±0.29 10.65±0.18 1.04±0.05 
F5 24.13±1.30 15.06±0.22 1.03±0.01 
F6 26.08±0.83 14.08±0.37 1.02±0.07 
F7 25.21±0.64 15.23±0.26 1.03±0.09 
F8 28.62±0.48 12.64±0.52 1.05±0.06 
F9  30.26±0.09  12.09±0.38 1.08±0.10 
F10 29.86±0.73  14.87±0.65 1.16±0.11 
F11 27.65±0.91 15.32±0.25 1.12±0.18 
F12 26.38±1.30 12.86±0.23 1.06±0.12 
F13 25.71±0.83 12.06±0.35 1.23±0.01 
F14 24.45±0.64 10.25±0.18 1.06±0.07 
F15  28.24±0.09  11.23±0.65 1.05±0.09 
F16 26.18±0.73 13.84±0.25 1.02±0.06 
 
Drug excipient compatibility studies 
Thermal properties of pure drug and the formulation were 
evaluated by Differential scanning calorimetry (DSC) using a 
diamond (DSC) (Mettler Star SW 8.10). The analysis was 
performed at a rate 50C min-1 to 2000C temperature range 
under a nitrogen flow of 25 ml min-1. 
Preparation of ATZ floating matrix tablets 
ATZ bisulfate and all other ingredients are accurately 
weighed and sifted through sieve 44. ATZ sulfate is well 
mixed with the number of required polymers of different 
grades (i.e. HPMC and EC) then mixed in geometric 
proportions. The above powder blend lubricated with 
magnesium stearate then lubricated blend is subjected to 
compression by required 8mm circular standard flat-faced 
punch on a sixteen station Cadmach rotary tablet punching 
machine.  
Evaluation of prepared ATZ floating matrix tablets 
The evaluation was performed to assess the physicochemical 
properties such as tablet thickness (mm), weight variation 
(mg), tablet hardness (kg/cm2), friability (%), drug content 
estimation (%), total floating time (TFT), in vitro dissolution 
studies and kinetics of drug releases15. 
In vitro dissolution studies 
The tablet was placed inside the dissolution vessel (USP 
XXIII) and operated with 50rpm. 5ml of the sample was 
withdrawn at time intervals of 1hr, 2hr, and 3hr, 4hr, 5hr, 
6hr, 7hr up to 24hours. The volume of dissolution fluid 
adjusted to 900ml by replacing 5ml of dissolution medium 
after each sampling. The release studies were conducted 
with 6 tablets and the mean values were plotted versus time. 
Each sample was analyzed at 250nm using a double beam 
UV-Visible spectrophotometer 16. 
Drug release kinetics 
The cumulative amount of drug released from different 
matrix tablets (containing different drug and polymer) at 
different time intervals was fitted to zero-order and first-
order kinetics. The data were also subjected to Higuchi’s 
model and diffusion parameters were estimated using 
Kerseymere’s equation17.  
Mt/M∞ = Ktn 
In which the value of exponent ‘n’ is indicative of the 
mechanism governing the release process of the drug from 
matrix tablets which are determined by taking log time on 
the X-axis log % release on the Y-axis 
Table 2: Analysis of diffusional drug release 
‘n’ values Mechanism 
0.5 Fickian diffusion 
0.5 < n < 1.0 Non – fickian diffusion 
1 Case II transport 
> 1.0 Super case II transport 
 
RESULTS AND DISCUSSION 
Preparation of ATZ standard curve 
Initially, the pure ATZ was scanned in the UV-range such as 
200-400 nm. The maximum absorbance for ATZ was found 
at 250nm. A standard concentration of ATZ in the range of 
10-70 µg/ml was prepared in 0.1N HCl and the absorbances 
were measured at 250nm. ATZ is showing good linearity 
between 10-50 µg/ml with a R2 of 0.993 (Figure 1).  
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Fig. 1: Standard curve of ATZ sulphate in 0.1N HCl 
 
Prototype formulation development of ATZ floating 
matrix tablets with EC 
The formulation of ATZ with EC was developed with the use 
of the drug and polymer ratio of (1:1) then pre-lubricated 
with magnesium stearate. Different grades of the EC used in 
the above formulations such as EC N20 (F-1), EC N22 (F-2), 
EC N45 (F-3), EC N50 (F-4) and EC N100 (F-5). To study the 
floating property, the prepared tablets were placed in 100ml 
of 0.1N HCl. The tablets were not floated and the tablet 
remained at the bottom of the glass beaker. This is mainly 
may be due to the high hardness of the tablets. The tablet 
was found to be like a tight compact and there are no void 
spaces for entrapment of the air and water. Based on the 
above observation, it was decided to reduce the tablet 
hardness in further formulation. The prepared formulations 
were evaluated for the floating property. The tablets were 
found to be floated but it was disintegrated in a short period. 
That was maybe due to the less hardness of the tablets.
 
Table 3: Formulation composition of the prepared ATZ Sulphate matrix tablets by the different grades of EC 
F CODE F1 F2 F3 F4 F5 
ATZ 100 100 100 100 100 
EC N20 100 
 
- - - 
EC N22 - 100 - - - 
EC N45 - - 100 - - 
EC N50 - - - 100 
 
EC N100 - - - - 100 
Magnesium stearate 2 2 2 2 2 
Tablet total weight 202 202 202 202 202 
 
Based on the above observations, further formulations were 
developed with a combination of EC and HPMC K100M to 
overcome the above problem. Three different grades were 
selected based on the viscosity of the polymers such as EC 
N22, EC N50, and EC N100. 
Formulation development of ATZ floating matrix tablets 
prepared with the combination of different grades of EC 
and HPMC K100M  
Floating matrix tablets of the ATZ were prepared by a 
combination of different grades of EC (i.e. EC N22, EC N50, 
and EC N100) and HPMC K100M. The drug and HPMC 
K100M were mixed and sifted through 44 sieves; the above 
blend was lubricated with magnesium stearate. The blend 
was compressed with an 8mm flat-faced punch at hardness 
around 5-6 kg/cm2. The tablets were evaluated for various 
physicochemical parameters and shown in Table 4.  
 
Table 4: Formulation composition of the prepared ATZ floating matrix tablets 
F CODE 
(mg/tablet) 
F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
ATZ 100 100 100 100 100 100 100 100 100 100 100 
EC N22 100 - - 100 - - 100 - - 100 - 
EC N50 - 100 - - 100 - - 100 - - - 
EC N100 - - 100 - - 100 - - 100 - 100 
HPMC K100 M 25 25 25 50 50 50 75 75 75 40 70 
Magnesium stearate 2 2 2 2 2 2 2 2 2 2 2 
Tablet total weight 227 227 227 252 252 252 277 277 277 242 272 
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In vitro drug release studies of ATZ floating matrix 
tablets prepared by combination of different grades of 
EC and HPMC K100M 
The In vitro dissolution study shows that the prepared ATZ 
matrix tablets extend the drug release up to 15 hours. The 
formulation F6 releases the complete drug in 9 hours. As the 
EC viscosity increased in the F7 and F8, drug release was 
extended up to 11-15hrs. The formulation F9 releases the 
complete drug in 20 hours. As the polymer viscosity 
increased in the F10, 97% of drug release observed in 24 
hours. In formulation F11, prepared by using EC N100, 85% 
of drug release was observed in 24 hours. In formulation 
F12, 91% of drug release was observed in 24 hours. As the 
polymer viscosity increased in the formulation F13, 84% of 
drug release was observed in 24hrs. Also as the polymer 
viscosity increased in the formulation F14, 72% of drug 
release was observed in 24hrs. The In vitro dissolution study 
shows that the prepared matrix tablet extends the drug 
release up to 24 hours (F15 and F16). As the polymer grade 
changed in the F16, the drug released was within 24hrs and 
drug release kinetics of all formulations (F6 to F16) was 
summarized in table 5. 
 
 
Fig. 2: Dissolution profiles of F6 to F8 formulations 
 
Fig 3: Dissolution profiles of F9 to F11 formulations 
 
 
Fig 4: Dissolution profiles of F12 to F14 formulations 
 
Fig 5: Dissolution profiles of F15 and F16 formulations
Table 5: Release kinetics of formulations prepared with combination of different grades of EC and HPMC K100M 
Kinetics F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
Zero order ( r2) 
0.943 0.982 0.989 0.984 0.996 0.996 0.998 0.997 0.995 0.997 0.996 
First order ( r2) 
0.895 0.864 0.796 0.778 0.811 0.919 0.905 0.929 0.952 0.722 0.819 
Higuchi ( r2) 
0.995 0.976 0.997 0.961 0.936 0.932 0.946 0.93 0.919 0.942 0.959 
Peppas ( n) 0.995 0.671 0.812 0.615 0.71 0.761 0.757 0.766 0.798 0.755 0.7 
 
In vitro buoyancy studies 
Based on the in vitro drug release and other physicochemical 
properties F10 formulation was optimized for further study. 
The tablets were dropped into 100ml of 0.1N HCl taken in 
250ml beaker. The tablets were observed for the floating 
time. Digital photographs were taken at initial, 3 hrs, 6 hrs, 
12 hrs, 18 hrs, and 24 hrs. The matrix tablets prepared with 
the combination of different grades of EC and HPMC K100 M 
remain floats for about 24hrs and more. Fig. 6 shows the 
photographs of floating property in the 0.1N HCl. 
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Fig. 6: In vitro buoyancy studies of optimized formulation (F10): (i) At initial time; (ii)  At 3 hours; (iii) At 6 hours; (iv) At 12 
hours; (v) At 18 hours; (vi) At 24 hours; 
 
Differential scanning calorimetric study (DSC) 
The DSC study was conducted on the selected formulations. 
DSC thermogram of pure ATZ shows sharp endothermic 
peak at 210.10C (shown in Figure 7) Similar endothermic 
peaks were obtained at 211.10C (shown in Figure 8) for the 
formulation prepared with EC, at 208.30C (shown in Figure 
9) for the physical mixture prepared with HPMC K 100 M, at 
210.60C (shown in Figure 10) for the formulation prepared 
with combination of EC and HPMC K 100 M. Table 6 
summarizes the DSC melting points of different 
concentrations. 
Table 6: DSC melting points of the selected formulations 
Formulations DSC melting points in 0C 
Pure ATZ 210.10C 
ATZ-EC 211.10C 
ATZ-HPMC K100 M 208.30C 
ATZ-EC-HPMC K100 M 210.60C 
 
 
Fig 7:  DSC thermograph of the pure ATZ 
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Fig 8:  DSC thermograph of the ATZ-EC. 
 
Fig 9:  DSC thermograph of the ATZ-HPMC K100 M 
 
Fig 10:    DSC thermograph of the ATZ-EC-HPMC K100M. 
In vivo radiographic studies 
The tablets were incorporated with 50mg of BaSO4 which 
was used in the various diagnostic tests. The tablets were 
given to the volunteers with a glass of water and a standard 
diet was provided. X-rays were taken at different time 
intervals such as 5min, 30min, 3hours, 6hours, and 9hours. 
(i.e.: Protocol number was KLRPC/IHEC/2010-2011/003).  
 
 
Table 7: Formulation table for X-ray radiographic study 
(modified F10 formulation). 
Ingredients Modified F10  
BaSO4 50 
EC N22 - 
EC N50 - 
EC N100 100 
HPMC K100 M 50 
MCC 50 
Mg stearate 2 
Final weight 252 
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Fig 11: In vivo radiographic studies of formulation F10 for with in 5min, 30min and 3hours 
 
Fig 12: In vivo radiographic studies of formulation F10 for 6hours and 9hours 
CONCLUSION 
In conclusion, HPMC K100M can be successfully employed in 
the preparation of controlled release floating tablets of ATZ. 
The formulations were prepared and succeeded without a 
gas generating agent. A combination of polymers can be 
successfully employed for better results. The research study 
provided useful information for the formulation of scientists 
working on the formulation, characterization during the 
development of controlled drug delivery systems of ATZ 
using these polymers. 
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